AVBP
ArriVent BioPharma, Inc.
Key Financials
Operating Income
$-177534000
↓ 88.2%
Net Income
$-166308000
↓ 106.6%
EPS (Diluted)
$-4.32
↓ 68.8%
Total Assets
$333.2M
↑ 21.2%
Shareholders' Equity
$307.2M
↑ 19.2%
Total Liabilities
$25.9M
↑ 50.1%
Cash & Equivalents
$45.5M
↓ 38.7%
Operating Cash Flow
$-160588000.00
↓ 128.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| SCHEDULE 13G/A | 7/27/2026 | View on SEC |
| 4 | 6/22/2026 | View on SEC |
| 4 | 6/22/2026 | View on SEC |
| 4 | 6/22/2026 | View on SEC |
| 4 | 6/22/2026 | View on SEC |
| 8-K | 6/22/2026 | View on SEC |
| 8-K | 5/11/2026 | View on SEC |
| 424B5 | 5/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AVBP |
| Company Name | ArriVent BioPharma, Inc. |
| CIK | 1868279 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 240-780-6356 |